CDNA

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy, today announced it will report financial results for the third quarter 2026 after market close on Thursday, October 29, 2026. The Company will host a webcast and conference call that day at 1:30 p.m. PT / 4:30 p.m. ET. A live and archived webcast of the conference call can be accessed on the Events & Presentations section of C.

CareDx (CDNA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

AMGN, BHC, CDNA and CNC offer defensive healthcare plays as inflation climbs and the Fed readies for a possible rate hike.

COCO, CHEF, ASMB and CDNA stand out as four defensive picks amid volatility induced by rising oil prices and Middle East tensions.

Here is how CareDx (CDNA) and Concentra Group (CON) have performed compared to their sector so far this year.

Does CareDx (CDNA) have what it takes to be a top stock pick for momentum investors? Let's find out.

CareDx, BrightSpring and PACS have been highlighted in this Industry Outlook article.

CareDx, BrightSpring and PACS Group are positioned for growth as digital health expands and workforce shortages reshape medical services.

Five stocks, including CareDx and Caterpillar, cleared an efficiency screen based on key ratios exceeding industry averages.

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy, today announced the award of inducement grants. On August 5, 2026, as an inducement material to acceptance of employment with CareDx, 35 new employees were awarded restricted stock units (RSUs) for an aggregate of 97,090 shares of common stock. With respect to 34 of the new employees, an aggregate of 93,090 of the RSUs will vest o.